Cartalax is a three-amino-acid peptide called AED (Ala-Glu-Asp) sold for joint and cartilage research. It comes from one Russian lab. It isn't FDA-approved. The PubMed evidence is a handful of preclinical papers, all from the same research network. Here's what the data actually shows.
Cartalax (AED tripeptide) belongs to the "short peptide bioregulator" family developed by the Khavinson group in Saint Petersburg. It's the cartilage-focused cousin of Epitalon (AEDG) and Pinealon (EDR). The published evidence is narrow. Only about 4 PubMed papers since 2015, all from one consortium, all preclinical. Zero Western RCTs exist for any clinical use. We'd call the evidence real but narrow, with no validated therapeutic role.
What Cartalax actually is
Cartalax is the vendor name for a synthetic tripeptide. The three amino acids are Ala-Glu-Asp (AED), and the molecular weight sits at about 333 Da. It is marketed under the "short peptide bioregulator" framework led by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology (Araj et al., 2025).
That program dates to the 1970s. AED is the catalog's "cartilage and connective-tissue" entry. It's marketed against the same theoretical framework as Epitalon (pineal) and Pinealon (brain). Whether AED actually reaches cartilage tissue at useful concentrations remains the unresolved question.
The Ashapkin 2020 paper: what the evidence actually shows
The most-cited piece of Cartalax-relevant literature is a 2020 paper from Ashapkin, Khavinson, and colleagues. It looked at gene-expression changes in aging human stem-cell cultures exposed to short peptides at nanomolar concentrations (Ashapkin et al., 2020).
Short peptides at nanomolar concentrations modulate gene-expression profiles in aging mesenchymal stem cell cultures, with peptide-specific patterns observed across IGF1, FOXO1, TERT, TNKS2, and NFκB.
— Ashapkin et al., 2020, Mol Biol Rep (paraphrased)
The headline: AED nudged 5 genes (IGF1, FOXO1, TERT, TNKS2, NFκB) in cell culture. That's the entire published case for Cartalax having any biological effect. One in-vitro paper. The joint-health marketing is an extrapolation from cell-culture data, not a cartilage-tissue outcome study.
The single-source-dominance problem
The evidence-quality issue that runs through the Epitalon literature applies more sharply here. Almost every paper on AED tripeptide comes from the Khavinson network. The proposed mechanism (direct binding to histones or DNA) parallels what the same group proposes for Epitalon and Pinealon (Khavinson et al., 2020).
For Epitalon, Brunel University London has at least replicated specific telomerase findings. For Cartalax, no equivalent independent Western confirmation exists as of mid-2026. That replication gap is the central limitation of the current evidence base.
Where this falls short. Zero Western RCTs evaluate Cartalax for osteoarthritis, cartilage repair, or any clinical use. The published mechanism rests on one in-vitro stem-cell paper from the originating consortium. The "cartilage tissue specificity" claim isn't a measured finding. It's a marketing extrapolation from cell-culture gene chips.
Cartalax research alternative
Cartalax is on the Peptriva research-content roadmap, but we don’t currently stock the AED tripeptide. For cartilage and joint research, our most-evidenced alternative is the BPC-157 / TB-500 blend — dozens of published preclinical studies on tendon, ligament, and connective-tissue applications. Browse the joint-research category for the full lineup.
Cartalax vs BPC-157 / TB-500 for joints
Comparing Cartalax against better-evidenced reference compounds for joint-biology research, the contrast is sharp:
- BPC-157. Dozens of rodent studies on Achilles tendon healing, MCL repair, and connective-tissue applications. Multiple independent groups in Croatia, Korea, and the U.S. Mechanistic support from new-blood-vessel-growth pathways.
- TB-500. Published tissue-repair and vessel-growth data across multiple groups. The parent molecule (thymosin β-4) has reached human clinical trials.
- Cartalax. One Khavinson-group cell-culture paper. No rodent joint-injury study. No in-vivo cartilage outcome study. No independent mechanistic replication.
Marketing claims vs published evidence
Here's what Cartalax vendor pages typically claim, alongside what the literature actually supports:
- "Supports cartilage regeneration." Extrapolated from in-vitro stem-cell gene expression. No cartilage-tissue study.
- "Increases joint mobility." No clinical data.
- "Reduces joint inflammation." Extrapolated from NFκB modulation in stem cells.
- "Used in Russian clinical practice." Category error. Russian approval doesn't validate Western use.
Legal and regulatory status
As of May 2026, Cartalax is not FDA- or EMA-approved for any use. In the U.S., it is sold only as a research reference compound labeled for laboratory use. Khavinson-school peptides have been used clinically in Russia under a different regulatory framework, but that does not validate use under Western standards.
Cartalax is not currently listed by name on the WADA Prohibited List. It is available strictly under Research Use Only labeling, with no supporting published clinical evidence for any human therapeutic indication.
Browse joint research peptides
Cartalax is on the research-content roadmap but not currently stocked. The most-evidenced alternative for cartilage and joint research is the BPC-157 / TB-500 family — dozens of independent preclinical studies on tendon, ligament, and connective-tissue biology. Lab-verified identity and purity with each lot, COA on request.
Frequently asked questions
What is Cartalax?
Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED). It was developed by the Khavinson group in Saint Petersburg. It belongs to the same "short peptide bioregulator" family as Epitalon (AEDG) and Pinealon (EDR). It's marketed for cartilage and joint research. No Western regulator has approved it.
What has Cartalax been studied for?
Preclinical research has investigated AED tripeptide in the context of cartilage biology, connective-tissue gene expression, and aging-related cellular processes. The biological rationale stems from a single 2020 Khavinson cell-culture study. No published RCTs have evaluated Cartalax for osteoarthritis or any clinical joint indication.
Is Cartalax FDA-approved?
No. Cartalax is not approved by the FDA, EMA, or any other Western regulator. In the U.S. it is sold only as a research reference compound, labeled for laboratory use only.
How does Cartalax work?
The proposed mechanism is direct gene regulation through histone or DNA binding. It's the same theoretical framework Khavinson uses for Epitalon and Pinealon. As of mid-2026, no independent Western lab has replicated the AED-specific mechanism in print.
Cartalax vs BPC-157 for joints: which has more evidence?
BPC-157 has dozens of rodent studies across multiple independent groups. Cartalax has one in-vitro paper. For joint biology, BPC-157 and the BPC-157 / TB-500 blend are the more-evidenced reference compounds.
Is the Russian Cartalax research credible?
The Khavinson group's work is methodically reported and isn't fraudulent. The issue is single-source dominance. Marketing claims significantly outpace independent Western replication. Russian-language clinical reports exist but aren't PubMed-indexed. For broader context, see our overview of Russian-school peptides.
What is the regulatory status of Cartalax for joint indications?
Cartalax is sold only as a research reference compound, available for laboratory use under Research Use Only labeling. No clinical trial data support any human therapeutic indication. Osteoarthritis affects over 595 million people globally (GBD 2021 Osteoarthritis Collaborators); approved treatment modalities evaluated in clinical research include exercise intervention, weight management, NSAIDs, and intra-articular injections. Cartalax has not been evaluated in any such clinical setting.
What to know now
- Identity: synthetic tripeptide Ala-Glu-Asp (AED), about 333 Da.
- Source: Khavinson group at the Saint Petersburg Institute of Bioregulation and Gerontology. Same consortium as Epitalon, Pinealon, Vesugen, Testagen.
- Published evidence: about 4 PubMed papers since 2015. All Khavinson-affiliated. All preclinical.
- Mechanism: proposed gene regulation via histone or DNA binding. Modulation of IGF1, FOXO1, TERT, TNKS2, and NFκB in stem cells at nanomolar concentrations.
- Clinical evidence: zero Western RCTs for any use.
- Regulatory: not FDA- or EMA-approved. Sold in the U.S. as research reference compound only.
- More-evidenced joint alternative: BPC-157 and the BPC-157 / TB-500 blend.
What we're watching
Two things to track for Cartalax over the next 24–36 months. First, whether any independent Western group publishes a non-Khavinson study of AED. We'd especially want to see chondrocyte or cartilage-explant work, where the joint-tissue claim could be directly tested. Second, whether the Brunel-style independent reassessment that's produced replication for Epitalon extends to AED. The single most informative experiment would be a rodent in-vivo osteoarthritis or tendon-injury study from a non-Khavinson lab. The absence of that study is the most consequential gap in the current evidence base.
References
- Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanyushin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: Modulation by short peptides. Molecular Biology Reports, 47(6), 4323–4329. https://doi.org/10.1007/s11033-020-05506-3
- Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of epitalon — Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
- Khavinson, V., Diomede, F., Mironova, E., et al. (2020). AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: Possible epigenetic mechanism. Molecules, 25(3), 609. https://doi.org/10.3390/molecules25030609
- GBD 2021 Osteoarthritis Collaborators. (2023). Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology, 5(9), e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7
- PubMed search: “AED tripeptide” OR “Cartalax” OR “Ala-Glu-Asp peptide”, 2015–2026. pubmed.ncbi.nlm.nih.gov